Findings {#Sec1}
========

Background {#Sec2}
----------

Smokers have an increased risk of peripheral arterial damage, which is associated with cardiovascular disease (CVD) events in patients with diabetes mellitus (DM) \[[@CR1]\]. Multi-faceted studies of subclinical peripheral arterial damage are thus important for prevention of CVD in patients with DM. Assessment of peripheral arterial damage is often conducted noninvasively using the ankle-brachial index (ABI) \[[@CR2], [@CR3]\]. Although ABI \< 0.9 has diagnostic value for peripheral arterial disease (PAD) \[[@CR2], [@CR3]\], a low-to-borderline level of ABI (0.9--1.1) is also associated with increased risk of CVD events and related mortality \[[@CR4], [@CR5]\].

A low ratio of serum eicosapentaenoic acid to arachidonic acid (EPA/AA) has also been correlated with CVD events in patients with DM \[[@CR6], [@CR7]\]. An additional study reported that the EPA/AA ratio was positively associated with the ABI level in hospitalized patients, although it did not take into account smoking habits or DM pathology \[[@CR8]\]. Recently, we reported that a low EPA/AA ratio is often seen in elderly patients with type 2 DM (T2DM), particularly in smokers \[[@CR9]\]. However, the association between the ABI and EPA/AA ratio has not been elucidated; therefore, in the present study, we aimed to investigate the correlation between ABI and EPA/AA among smokers with T2DM.

Subjects and methods {#Sec3}
--------------------

### Study participants {#Sec4}

A cross-sectional study of 116 smoking and non-smoking T2DM patients (2 groups of 50 men and 8 women, mean age 59 yr in each group) who visited the Jichi Medical University Hospital, Shimotsuke, Japan for more 1 yr was conducted from April to September 2014. Smoking habits were confirmed via self-reports. Current smoking status was designated as either smoking or not smoking. None of the patients were taking medications containing EPA or AA. We excluded patients with a history of CVD events, recent acute illness, systemic inflammatory disease, severe nephropathy (i.e., stage 3--5), liver dysfunction, type 1 DM, and PAD. The study was approved by the Jichi Medical University Ethical Committee and informed consent was obtained from all patients.

Hypertension was defined as systolic blood pressure (SBP) ≥ 140 mm Hg, diastolic blood pressure ≥ 90 mm Hg, and/or anti-hypertensive drug use \[[@CR10]\]. Nephropathy was defined as a urinary albumin-to-creatinine ratio \> 30 mg/g creatinine, above the micro albuminuria level \[[@CR11]\].

### Data collection {#Sec5}

Fasting blood samples were collected at the outpatient clinic to measure levels of glucose, hemoglobin A1c (HbA1c), total cholesterol, triglycerides, high-density lipoprotein cholesterol, EPA, and AA. A high-performance liquid chromatography system (HLA-723G8; Tosoh Corp., Tokyo, Japan) was used to measure HbA1c. Serum lipids were extracted by Folch's method and the fatty acids (internal standard, tricosanoic acid \[C23:0\]) were methylated with boron trifluoride and methanol. EPA and AA levels in the methylated fatty acids were then analyzed by gas chromatography (GC-2010; Shimadzu Corp., Kyoto, Japan) with a capillary column (TC-70; GL Sciences Inc., Tokyo, Japan).

The ABI was determined using a pulse pressure analyzer (model BP-203RPEIII; Omron Colin Corp., Tokyo, Japan) as previously described \[[@CR12]\]. ABI was determined based on the SBP in both the upper (brachial arterial) and lower (tibial arterial) arteries \[[@CR13]\] and was calculated by dividing the ankle SBP by the brachial SBP. The patient population was divided into two ABI groups (\<1.1 and ≥1.1) based on previous studies \[[@CR4], [@CR14]\].

### Statistical analysis {#Sec6}

Smoking and non-smoking patients were matched for age and sex. Comparisons between smoking and non-smoking groups were conducted using an unpaired *t*-test or chi-square test. Differences in parameters between ABI groups were analyzed using an unpaired *t*-test or chi-square test. Correlations between absolute ABI and the other parameters (including the EPA/AA ratio) were examined using a Pearson's correlation test and stepwise multiple regression analysis (SPSS software; SPSS Inc., IL, USA). All parameters were included in the stepwise multiple regression model except for the EPA, which was not included due to multicollinearity with the EPA/AA ratio and the stronger correlation of the EPA/AA ratio with the ABI. Parameters with skewed distributions were log-transformed prior to all analyses. A *p*-value of \<0.05 was considered to be significant.

Results {#Sec7}
-------

Clinical characteristics of the study population for the smoking and non-smoking groups are shown in Table [1](#Tab1){ref-type="table"}. The HbA1c level and percentage with neuropathy complications were higher in the smoking group than in the non-smoking group.Table 1Clinical characteristics of the study population by current smoking habitParameterNon-smoker (*n* = 58)Smoker (*n* = 58)*p*Age, yr59 ± 1259 ± 100.91Sex, male (%)50 (86 %)50 (86 %)1.00Body mass index, kg/m^2^26.3 ± 4.426.2 ± 4.50.88Systolic blood pressure, mm Hg131 ± 14131 ± 110.80Diastolic blood pressure, mm Hg77 ± 1179 ± 100.43Antihypertensive drugs, *n* (%)33 (57 %)43 (74 %)0.05Glucose, mg/dL149 ± 62139 ± 420.29Hemoglobin A1c, %7.2 ± 1.07.6 ± 1.00.045\*Insulin injection, *n* (%)15 (26 %)14 (24 %)0.83Retinopathy, *n* (%)18 (31 %)23 (40 %)0.33Neuropathy, *n* (%)24 (41 %)36 (62 %)0.03\*Nephropathy, *n* (%)19 (33 %)25 (43 %)0.25LDL cholesterol, mg/dL97 ± 3195 ± 330.73HDL cholesterol, mg/dL60 ± 1755 ± 160.13Triglycerides, mg/dL114 (73--160)125 (91--173)0.19Statin drugs, *n* (%)21 (36 %)22 (38 %)0.85AA, μg/mL173 (151--212)181 (152--234)0.49EPA, μg/mL60 (41--96)52 (36--86)0.28EPA/AA ratio0.37 (0.23--0.56)0.29 (0.19--0.42)0.08Ankle-brachial index1.14 ± 0.071.11 ± 0.090.07Data are means ± standard deviations, medians (interquartile ranges), or numbers (%)*LDL* low-density lipoprotein, *HDL* high-density lipoprotein, *AA* arachidonic acid, *EPA* eicosapentaenoic acid\* *p* \< 0.05 for comparison between groups by smoking (*t*-test or chi-square test)

Two patients with ABI \< 0.9 (the defined PAD level) were included in the smoking group. In the smoking group, patients with ABI \< 1.1 had significantly lower EPA/AA ratios than did those with ABI ≥ 1.1, while the AA and EPA alone did not show clear differences between patients with ABI \< 1.1 and ≥ 1.1. The other parameters were not statistically different between the groups (Table [2](#Tab2){ref-type="table"}). In contrast, patients with ABI ≤ 1.1 had a significantly higher HbA1c than did those with ABI ≥ 1.1 in the non-smoking group. There were no statistical differences in the other parameters, including EPA/AA, with ABI levels in the non-smoking group.Table 2Clinical characteristics of the study population by ABI (\<1.1 and ≥ 1.1)Non-smoker*p*Smoker*p*ParameterABI \< 1.1 (*n* = 17)ABI ≥ 1.1 (*n* = 41)ABI \< 1.1 (*n* = 26)ABI ≥ 1.1 (*n* = 32)Age, yr56 ± 1460 ± 110.2158 ± 1060 ± 110.61Sex, male (%)15 (88 %)35 (85 %)0.7722 (85 %)28 (88 %)0.75Body mass index, kg/m^2^26.5 ± 5.626.2 ± 3.90.7725.5 ± 3.826.7 ± 5.00.31Systolic blood pressure, mm Hg133 ± 17130 ± 130.45131 ± 10132 ± 120.77Diastolic blood pressure, mm Hg80 ± 1376 ± 100.2279 ± 978 ± 100.76Antihypertensive drugs, *n* (%)12 (71 %)21 (51 %)0.1820 (77 %)23 (72 %)0.66Glucose, mg/dL157 ± 39146 ± 700.55137 ± 42140 ± 430.74Hemoglobin A1c, %7.7 ± 1.27.0 ± 0.80.01\*7.6 ± 1.07.5 ± 1.00.82Insulin injection, *n* (%)7 (41 %)8 (20 %)0.093 (12 %)11 (34 %)0.06Retinopathy, *n* (%)6 (35 %)12 (29 %)0.659 (35 %)14 (44 %)0.48Neuropathy, *n* (%)10 (59 %)14 (34 %)0.0810 (38 %)15 (47 %)0.52Nephropathy, *n* (%)5 (29 %)14 (34 %)0.7316 (62 %)20 (63 %)0.94LDL cholesterol, mg/dL96 ± 3897 ± 280.8895 ± 3994 ± 280.95HDL cholesterol, mg/dL61 ± 1859 ± 160.6852 ± 1457 ± 180.23Triglycerides, mg/dL127 (79--217)107 (69--144)0.18139 (116--233)118 (83--159)0.09Statin drugs, *n* (%)6 (35 %)15 (37 %)0.9313 (50 %)9 (28 %)0.09AA, μg/mL176 (144--214)173 (150--210)0.51191 (158--244)180 (134--227)0.18EPA, μg/mL64 (46--114)60 (41--97)0.2649 (33--69)68 (41--96)0.07EPA/AA ratio0.44 (0.21--0.75)0.37 (0.23--0.55)0.560.25 (0.16--0.40)0.34 (0.20--0.69)0.03\*Ankle-brachial index1.06 ± 0.041.17 ± 0.05\<0.01\*\*1.03 ± 0.061.18 ± 0.05\<0.01\*\*Data are means ± standard deviations, medians (interquartile ranges), or numbers (%)*LDL* low-density lipoprotein, *HDL* high-density lipoprotein, *AA* arachidonic acid, *EPA* eicosapentaenoic acid\* *p* \< 0.05, \*\* *p* \< 0.01 for comparison between ABI groups (*t*-test or chi-square test)

Correlations of absolute ABI with the other parameters are listed in Table [3](#Tab3){ref-type="table"}. Pearson's correlation tests found that EPA and the EPA/AA ratio were significantly and positively correlated with ABI levels in the smoking group, while HbA1c was significantly and negatively correlated with ABI levels in the non-smoking group. Stepwise multiple regression analysis revealed that the EPA/AA ratio was independently, significantly, and positively correlated with ABI levels and that use of statin drugs was inversely correlated with ABI levels in the smoking group, while HbA1c was independently, significantly, and negatively correlated with ABI levels in the non-smoking group.Table 3Correlations between the absolute value of the ankle-brachial index and other parametersNon-smokerSmokerParameter*r* (*p*)*β* (*p*)*r* (*p*)*β* (*p*)Age, yr0.23 (0.09)NE0.06 (0.67)NESex, male (%)0.14 (0.31)0.19 (0.12)0.03 (0.81)NEBody mass index, kg/m^2^−0.07 (0.61)NE0.05 (0.70)NESystolic blood pressure, mm Hg−0.05 (0.71)NE−0.04 (0.78)NEDiastolic blood pressure, mm Hg−0.11 (0.41)NE−0.13 (0.35)NEAntihypertensive drugs, *n* (%)−0.15 (0.27)NE−0.10 (0.45)NEGlucose, mg/dL−0.16 (0.25)NE0.03 (0.85)NEHemoglobin A1c, (%)−0.46 (\<0.01\*\*)−0.45 (\<0.01\*\*)0.01 (0.95)NEInsulin injection, *n* (%)−0.21 (0.12)NE0.19 (0.14)0.26 (0.06)Retinopathy, *n* (%)−0.02 (0.91)NE−0.08 (0.54)NENeuropathy, *n* (%)−0.18 (0.18)NE−0.04 (0.79)NENephropathy, *n* (%)0.08 (0.58)NE−0.05 (0.73)NELDL cholesterol, mg/dL−0.01 (0.95)NE−0.05 (0.72)NEHDL cholesterol, mg/dL0.06 (0.67)NE0.22 (0.10)NETriglycerides, mg/dL−0.22 (0.11)−0.16 (0.17)−0.16 (0.27)NEStatin drugs, *n* (%)−0.12 (0.37)NE−0.15 (0.26)−0.31 (0.03\*)AA, μg/mL0.04 (0.78)--−0.13 (0.32)--EPA, μg/mL−0.19 (0.16)--0.28 (0.04\*)--EPA/AA ratio0.05 (0.73)NE0.31 (0.02\*)0.41 (\<0.01\*\*)*LDL* low-density lipoprotein, *HDL* high-density lipoprotein, *AA* arachidonic acid, *EPA* eicosapentaenoic acid, *NE* not extracted; −: not used in the analysis. Data are Pearson's *r* correlation coefficients and standardized *β* coefficients from stepwise multiple regression analysis\* *p* \< 0.05, \*\* *p* \< 0.01

Discussion {#Sec8}
----------

We found that the EPA/AA ratio was lower in patients with ABI \< 1.1 than in those with ABI ≥ 1.1, with a positive correlation between the EPA/AA ratio and ABI in smokers with T2DM. To our knowledge, a relationship between the EPA/AA ratio and ABI level among smokers or non-smokers with T2DM has not previously been reported. Accordingly, the results of this study suggest that the EPA/AA ratio may be associated with subclinical PAD in smokers with T2DM.

By contrast of n-3 fatty acids, particularly EPA, n-6 fatty acids, particularly AA, impair peripheral arteries by creating vasoactive oxygen radicals and promoting cyclooxygenase metabolism \[[@CR15], [@CR16]\]. In smokers, a delayed conversion of AA to eicosanoids is known \[[@CR17]--[@CR19]\], this may result in endothelial dysfunction in peripheral arteries \[[@CR20]\]. This is a possible mechanism for a positive correlation between the EPA/AA ratio and ABI levels in smokers with DM, although this requires further research.

Based on the results of our stepwise regression model, ABI was inversely associated with the use of statin drugs in the smoking group. Statins are often prescribed for patients with DM, particularly when the patients may have complications of DM. As a result, patients with subclinical PAD may use statins. This is only a hypothesis; however, similar results were reported in a previous study \[[@CR21]\].

The present study had certain limitations. It was a cross-sectional study with a small sample size; thus, further intervention and a placebo control study are needed. Additionally, as there was no information regarding dietary fish consumption, smoking dose, or smoking duration (e.g., the Brinkman index), and because the cigarette type was not investigated in detail, these factors could not be considered in our analysis.

Conclusions {#Sec9}
-----------

In summary, the EPA/AA ratio may be associated with subclinical PAD in smokers with T2DM. The utility of measuring the EPA/AA ratio along with ABI should be further investigated in future studies.
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